Sectors

OCGN
Ocugen, Inc.
1.04
87 x 0.90
105 x 1.04
bid
ask
-
0.02
1.89%
10:07 AM
timesize
Ytd-22.96%
1y-22.39%
1.03
day range
1.08
0.97
52 week range
2.73
Open1.05Prev Close1.06Low1.03High1.08Mkt Cap349.28M
Vol747.85KAvg Vol6.84MEPS-0.26P/EN/AForward P/E-2.85
Beta2.20Short Ratio14.01Inst. Own27.53%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0550-d Avg1.29200-d Avg1.511yr Est6.25

OCGN News

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances
marketbeat.com
Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submission

What's Happening With Ocugen Stock Thursday?
benzinga.com
What's Happening With Ocugen Stock Thursday?

Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing in

benzinga.com
HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula

benzinga.com
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene

The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in g

benzinga.com
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consens

benzinga.com
FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic A

RMAT designation is intended to help expedite development of new regenerative medicines that have po

benzinga.com
Ocugen To Enter License Agreement With Roots Pharmaceutical For Rights To OCU400, Its Novel Modifier

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRo

benzinga.com
Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11

Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Full Transcript: Ocugen Q1 2026 Earnings Call
benzinga.com
Full Transcript: Ocugen Q1 2026 Earnings Call

benzinga.com
Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens

GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
benzinga.com
GeneDx Holdings, Duolingo, Kosmos Energy And Other Big Stocks Moving Lower In Tuesday's Pre-Market S

Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance

Earnings Scheduled For May 5, 2026
benzinga.com
Earnings Scheduled For May 5, 2026

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

benzinga.com
Ocugen Plans To Commence $115M Senior Notes Offering

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

benzinga.com
HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy

Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls
benzinga.com
Ocugen Eye Disease Gene Therapy Data Trails Earlier Results, Stocks Falls

Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu

benzinga.com
Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Second

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth

benzinga.com
Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12

Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati

Why Is Ocugen Stock Soaring Today?
benzinga.com
Why Is Ocugen Stock Soaring Today?

Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday
benzinga.com
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving High

Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected

This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
benzinga.com
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations Fo

Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r

benzinga.com
Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10

Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform

Earnings Summary: Ocugen Q4
benzinga.com
Earnings Summary: Ocugen Q4

benzinga.com
Ocugen Q4 EPS $(0.06), Inline, Sales $(193.000K) Miss $860.000K Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus

Earnings Scheduled For March 4, 2026
benzinga.com
Earnings Scheduled For March 4, 2026

Examining the Future: Ocugen's Earnings Outlook
benzinga.com
Examining the Future: Ocugen's Earnings Outlook

benzinga.com
Ocugen Completes Enrollment In Late-Stage Blindness Trial, Eyes FDA Filing In 2026

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering
benzinga.com
Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering

Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte

Ocugen Stock Is Surging Today: What's Driving The Action?
benzinga.com
Ocugen Stock Is Surging Today: What's Driving The Action?

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi

Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage
benzinga.com
Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage

Ocugen reports early phase 2 data showing its eye gene therapy reduced lesion growth by up to 54%, w

OS Therapies Bone Cancer Trial Data Strengthens FDA Case
benzinga.com
OS Therapies Bone Cancer Trial Data Strengthens FDA Case

OS Therapies releases trial data supporting FDA approval, U.K. and U.S. timelines, and potential eli

benzinga.com
Ocugen Announces Preliminary 12-Month Data From Phase 2 ArMaDa Clinical Trial Evaluating OCU410 For

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. cont

benzinga.com
Ocugen Announces Publication Of Positive Phase 1 Gardian1 Trial Results For OCU410ST, Modifier Gene

Study supports favorable safety and tolerability profile and clinically meaningful functional and st

benzinga.com
Ocugen Q3 Sales $1.752M Beat $550.000K Estimate

Ocugen (NASDAQ:OCGN) reported quarterly sales of $1.752 million which beat the analyst consensus est

Earnings Scheduled For November 5, 2025
benzinga.com
Earnings Scheduled For November 5, 2025

benzinga.com
Forecasting The Future: 4 Analyst Projections For Ocugen

benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session

Ocugen Shares Are Trading Higher Monday: What's Going On?
benzinga.com
Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwang

benzinga.com
Ocugen Strikes $7.5M Licensing Deal Giving Kwangdong Exclusive Korean Rights To Gene Therapy For Bli

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l

benzinga.com
Carisma Therapeutics To Receive $5M Investment From Ocugen As Part of Merger With Ocugen Subsidiary

 

benzinga.com
The Committee For Medicinal Products For Human Use Of The European Medicines Agency Reviewed The Stu

With enrollment scheduled to be complete in the first quarter of 2026 the Company remains on track f

benzinga.com
Ocugen Announces $20M Direct Offering Of 20M Shares And 20M Warrants At A Combined Price Of $1.00

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap

benzinga.com
Demystifying Ocugen: Insights From 5 Analyst Reviews

benzinga.com
Chardan Capital Maintains Buy on Ocugen, Maintains $7 Price Target

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $

benzinga.com
Ocugen Q2 EPS $(0.05) Beats $(0.06) Estimate, Sales $1.373M Beat $350.000K Estimate

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus

benzinga.com
Earnings Scheduled For August 1, 2025